Q-omics provides the consensus-scored TPTE2P3 profile across patient tissues and cancer cell-line models. TPTE2P3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TPTE2P3 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, TPTE2P3 RNA expression shows 15,448 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRP, and THYM as cancer lineages where TPTE2P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPTE2P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPTE2P3 survival associations across molecular data types. TPTE2P3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPTE2P3 RNA expression–survival associations across cancer types. High TPTE2P3 expression shows unfavorable associations in HNSC and BLCA, but favorable associations in UVM, MESO, BRCA and ACC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TPTE2P3 RNA expression.
This table summarizes TPTE2P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for TPTE2P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPTE2P3 shows lower tumor expression in KIRP, KICH, KIRC, UCEC, BRCA and BLCA. The KIRP box plot shows higher TPTE2P3 RNA expression in normal versus tumor tissue (log2 FC = −0.989, t-test p < 0.001).
This table shows molecular features associated with TPTE2P3 in patient tissues and cancer cell lines. In patient samples, TPTE2P3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TPTE2P3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
